The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The use of hydroxyurea for treating SCD in Sub-Saharan Africa
Leon Tshilolo, MD, PhD, Centre Hospitalier Monkole, Kinshasa, DR Congo, discusses the use of hydroxyurea for the treatment of sickle cell disease (SCD) in sub-Saharan Africa (SSA), highlighting the main limitations to the widespread implementation of this agent. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novo Nordisk, Pfizer.
